¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Ascorbic Acid Coated 96% Type SC"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • wild type
    ¾ß»ýÇü
  • wild type strain
    ¾ß»ýÁÖ
  • anthranilic acid
    ¾ÈÆ®¶ó´Ò»ê
  • anti-double stranded deoxyribonucleic acid antibody
    Ç×ÀÌÁß°¡´ÚDNAÇ×ü
  • arachidonic acid
    ¾Æ¶ó۵·»ê
  • arsenic acid
    ºñ»ê
  • aspartic acid
    ¾Æ½ºÆÄÆ®»ê
  • acetic acid
    ¾Æ¼¼Æ®»ê
  • acetoacetic acid
    ¾Æ¼¼Å侯¼¼Æ®»ê
  • acetylsalicylic acid
    ¾Æ¼¼Æ¿»ì¸®½Ç»ê
  • acetylsalycylic acid antiplatelet therapy
    ¾Æ¼¼Æ¿»ì¸®½Ç»êÇ×Ç÷¼ÒÆÇ¿ä¹ý
  • acid
    Ȑ
  • acid alcohol
    »ê¼º¾ËÄÚ¿Ã
  • acid burn
    »êÈ­»ó
  • acid challenge test
    »êÅõ¿©°Ë»ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • acid fast organism
    Ç×»ê±Õ
  • acid radical
    »ê±â
  • acid salt
    »ê¼º¿°
  • acid-fast stain
    Ç׻꿰»ö
  • acetylsalycylic acid antiplatelet therapy
    Ç×Ç÷¼ÒÆÇ¿ä¹ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • parthenogenetic type
    ´Ü¼º»ý½ÄÇü
  • polymyarian type
    ´Ù±ÙÀ°Çü
  • propagative type
    Áõ½ÄÇü
  • pyknic body type
    ºñ¸¸½ÅüÇü
  • split-electrode-type probe
    ºÐÇÒÀü±Ø´õµëÀÚ
  • storage-type
    ÃàÀûÇü
  • scirrhous type
    °æÈ­Çü
  • simple type schizophrenia
    ´Ü¼øÁ¤½ÅºÐ¿­º´
  • sthenic type
    ±Ù·ÂÇü
  • sympathicotonic type
    ±³°¨½Å°æ±äÀåÇü
  • type species
    Ç¥ÁرÕÁ¾
  • type specificity
    ÇüƯÀ̼º
  • type specimen
    ±âÁØÇ¥º»
  • type strain
    Ç¥ÁرÕÁÖ
  • type
    Çü, À¯Çü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • hyperlipoproteinemia type III
    °íÁö´Ü¹éÇ÷Áõ III
  • hyperlipoproteinemia type IV
    °í´Ü¹éÇ÷Áõ IV Çü
  • hyperlipoprotenemia type II
    °íÁö´Ü¹éÇ÷Áõ II Çü
  • hyperproteinemia type III
    ´Ü¹é°úÀ×Ç÷(Áõ) III Çü
  • hypersensitivity reactions,delayed-type
    Áö¿¬Çü(òÀæÅû¡)
  • hypersensitivity reactions,type i(anaphylactic)
    IÇü
  • hypersensitivity reactions,type ii(antibody-dependent cell-mediate cyt
    IIÇü
  • hypersensitivity reactions,type iii(imune complex-mediated)
    IIIÇü
  • hypersensitivity reactions,type iv(cell-mediated)
    IVÇü
  • hypersensitivity, delayed-type
    Áö¿¬Çü °ú¹Î¹ÝÀÀ
  • hypersensitivity, immediate-type
    Áï½ÃÇü °ú¹Î¹ÝÀÀ
  • hypertrophic type
    ºñ´ëÇü
  • hypogammaglobulinemia, Swiss-type
    ½ºÀ§½ºÇü °¨¸¶±Û·ÎºÒ¸°ÀúÇ÷Áõ
  • personality disorder, mixed type
    È¥ÀçÇü(ûèî¤úþ) ÀΰÝÀå¾Ö
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • diagnostic type protective tube housing
    ÁøÂûÇü¹æÈ£¿ë ¿¢½º¼±°ü¿ë±â.
  • diploic type
    ÆÇ»çÀÌÇü, ÆÇ°£Çü(÷ùÊàúþ).
  • dorsolumbal type
    Èä¿äºÎ Çü(ýØé¦Ý»úþ), ¹èÃø ¿äºÎ Çü(ÛÎö°é¦Ý»úþ), ¹è¿ä Çü, Èä¿ä Çü.
  • dromedary type
    ´ÜºÀÇü.
  • dysplastic type
    ¹ßÀ°ºÎÀüü°Ý(Û¡ëÀÝÕîïô÷Ì«).
  • elastic type of artery
    ź·ÂÇüµ¿¸Æ
  • encephalopathy of multifocal type
    ´ÙÃÊÁ¡¼º ³úº´Áõ.
  • enchondral type
    ³»¿¬°ñ Çü(¡­úþ).
  • expansive type
    °ú´ëÇü(ΣÓÞû¡).
  • facioscapulohumeral type
    ¾È¸é°ß°©»ó¿ÏÇü(¡­ß¾èÓúþ).
  • fever type
    ¿­Çü(æðúþ).
  • fibrous type dermatofibroma
    ¼¶À¯Çü ÇǺΠ¼¶À¯Á¾
  • fibrous type of lymphatic vessel
    ¼¶À¯Çü¸²ÇÁ°ü
  • fibrous type of vein
    ¼¶À¯ÇüÁ¤¸Æ
  • foreign body-type giant cell
    À̹°Çü °Å´ë¼¼Æ÷(¡­ËÝÓÞá¬øà)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • acid-base titration
    »ê¿°±â ÀûÁ¤ (ß«ç¤ÐñîêïÒ)
  • acid-citrate-dextrose solution
    »ê(ß«)-½ÃÆ®¸£»ê-(ß«)µ¦½ºÆ®·Î½º ¿ë¾×(éÁäû)
  • acid-fast
    Ç׻꼺 (ù÷ß«àõ)
  • acid-thiol ligase
    »ê(ß«)ŸÀ̿öóÀ̰ÔÀ̽º
  • acidic amino acid
    »ê¼º(ß«àõ)¾Æ¹Ì³ë»ê(ß«)
  • active amino acid
    Ȱ¼º(üÀàõ)¾Æ¹Ì³ë»ê (ß«)
  • adenylic acid
    ¾Æµ¥´Ò»ê(ß«)
  • aldaric acid
    ¾Ë´Ù¸£»ê(ß«)
  • aldonic acid
    ¾Ëµ·»ê(ß«)
  • alginic acid
    ¾Ë±ä»ê(ß«)
  • alpha amino acid
    ¾ËÆÄ¾Æ¹Ì³ë»ê(ß«)
  • amino acetic acid
    ¾Æ¹Ì³ë¾Æ¼¼Æ®»ê(ß«)
  • amino acid
    ¾Æ¹Ì³ë»ê(ß«)
  • amino acid accepting RNA
    ¾Æ¹Ì³ë»ê(ß«) ¼ö³³(áôÒ¡)RNA
  • amino acid activating enzyme
    ¾Æ¹Ì³ë»ê(ß«) Ȱ¼ºÈ­(üÀàõûù) È¿¼Ò(ý£áÈ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
AA abdominal aorta; acetic acid; achievement age; active alcoholic; active assistive [range of motion];...
OA obstructive apnea; occipital artery; occipito-anterior; occiput anterior; octanoic acid; ocular albi...
PAA partial agonist activity; phenylacetic acid; phosphonoacetic acid; physical abilities analysis; plas...
ACB antibody-coated bacteria; aortocoronary bypass; arterialized capillary blood; asymptomatic carotid b...
ACGT antibody-coated grid technique
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
HIV-2 Human Immunodeficiency Virus type 1 and type 2
HSV 2 herpes simplex virus type 1 or type 2
Type 1 type
type I type B
GABAA Gamma-aminobutyric acid Type A
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • muscle tension type headache
    ±Ù ±äÀ强 µÎÅë
    ÈĵκÎ, Ç׺ÎÀÇ Áö¼ÓÀûÀÎ ¾Ð¹Ú°¨, ±³¾×°¨À» È£¼ÒÇÑ´Ù. ÀÌ ÁõÀÇ È¯ÀÚ´Â ½Å°æÁú·Î ±äÀåÇϱ⠽¬¿î »ç¶÷¿¡°Ô ¸¹°í °³Ã¼ÀÇ ±Ù±äÀ强¼ÒÀΰú ¾î¿ï¾îÁ® ±ÙÀÇ Áö¼ÓÀû ¼öÃà°ú ±ÙÀÇ ¼øÈ¯ ºÎÀü ¡æ ÅëÁõ ¹°Áú ¹ß»ý ¡æ ÅëÁõ ¡æ ±Ù ¼öÃàÀ̶ó´Â ¾Ç¼øÈ¯ÀÌ Çü¼ºµÇ´Â °ÍÀ¸·Î »ý°¢µÈ´Ù. Á÷¾÷¿¡ µû¸¥ ºÎÀÚ¿¬½º·¯¿î ÀÚ¼¼°¡ °ü·ÃÀÌ ÀÖ´Â °æ¿ìµµ ¸¹°í ½Åü, ½É¸®Àû ¾çÃø¸éÀ¸·ÎºÎÅÍÀÇ Á¢±ÙÀÌ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹´Ù.
  • muscular type of vein
    ±ÙÀ°Çü Á¤¸Æ
  • nonnecrotizing type
    ºñ±«»ç¼º ÇüÅÂ
  • oral-facial-digital syndrome, type I
    IÇü±¸-¾È¸é-ÁöÁõÈıº
    X-¿¬°ü¼º ¿ì¼º À¯Àüº´À¸·Î¼­ ³²ÀÚ¿¡°Ô´Â Ä¡¸íÀûÀ¸·Î ±¼ÁöÁõ, ´ÙÁöÁõ, ÇÕÁöÁõ µîÀÌ Æ¯Â¡À̸ç, µÎ°³, ¾È¸é, ¼³, ±¸°³ ¹× ÇÏ¾Ç ±âÇüÀ» ¼ö¹ÝÇϰųª Áö´É ÀúÇÏ, Å»¸ðÁõ, ¾È¸é Áö·ç¸¦ ¼ö¹ÝÇÑ´Ù.
  • pedunclated type
    À¯°æÇü
  • personality type
    Àμº
  • pontic of root extension type
    À¯±Ù °¡°øÃ¼
    ¼ÒÇüÀÇ Ä¡±ÙÀ» °¡Áö°í ¹ßÄ¡¿Í ¼Ó¿¡ ÀûÇյǴ °¡ °øÃ¼, Ä¡°æºÎ¿Í ÇüÅ ±×¸®°í Ä¡Àº¿¬°úÀÇ °ü°è°¡ ÀÚ¿¬¿¡ °¡±õ°í ½É¹ÌÀûÀÌ°í °¡Àå ¿ì¼öÇϸç, ÀåÂø ÈÄ Ä¡ÀºÀÌ ¾à°£ ÅðÃàÇÏ¿©µµ °¡°øÃ¼¿ÍÀÇ »çÀÌ¿¡ °ø±ØÀÌ »ý±âÁö ¾Ê°í »ç¿ë°¨µµ ¾çÈ£ÇÏ´Ù. ´ë°³ Áï½Ã °¡°ø ÀÇÄ¡·Î¼­ ¹ßÄ¡ Á÷ÈÄ¿¡ ÀåÂøµÈ´Ù.
  • precision type attachment
    Á¤¹ÐÇü ºÎÂø ÀåÄ¡
  • pseudohypertrophic type
    °¡¼º ºñ´ëÇü
  • recurring type
    Àç¹ß¼º
  • repository type of penicillin
    ÀúÀåÇü Æä´Ï½Ç¸°
  • salivary gland type
    Ÿ¾×¼± À¯Çü
  • schizoaffetive type
    ºÐ¿­ Á¤µ¿Çü, ºÐ¿­ Á¤°¨Çü
  • schizoid type
    ºÐ¿­Çü
  • schizophrenia of childhood type
    ¾Æµ¿Çü Á¤½Å ºÐ¿­Áõ
    »çÃá±â¿¡ ¹ßº´ÇÏ´Â Á¤½Å ºÐ¿­ÁõÀ¸·Î¼­ ÀÚÆó¼º, ³»Ç⼺, ºñÁ¤ÇüÀû ÇൿÀ» Ư¡À¸·Î ÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
glycogen storage disease type IV <disease> An autosomal recessive metabolic disorder due to a deficiency in expression of branching enzyme (alpha-1,4-glucan-6-alpha-glucosyltransferase), resulting in an accumulation of abnormal glycogen with long outer branches. Clinical features are muscle hypotonia and cirrhosis. Death from liver disease usually occurs before age 2.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type V <disease> Glycogenosis due to muscle phosphorylase deficiency. Characterised by painful cramps following sustained exercise.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VI <disease> A hepatic glycogen storage disease in which there is an apparent deficiency of hepatic phosphorylase activity. However, studies have not been able to distinguish between phosphorylase deficiency and phosphorylase kinase deficiency in patients with hepatic glycogenosis.
(12 Dec 1998)
glycogen storage disease type VII <disease> An autosomal recessive muscle glycogen storage disease in which there is deficient expression of muscle phosphofructokinase activity, resulting in increased concentrations of glucose-6-phosphate and fructose-6-phosphate and low concentrations of fructose-1,6-diphosphate in muscle tissue.
Glycogen storage in muscle is increased, perhaps due to activation of glycogen synthase by accumulated glucose-6-phosphate. It has been proposed that shunting of glucose-6-phosphate and fructose-6-phosphate into the pentose phosphate pathway may result in increased synthesis of purines and pyrimidines, causing hyperuricaemia and gout.
Erythrocytes from patients may show decreased phosphofructokinase activity and 2,3-diphosphoglycerate deficiency. Exercise intolerance is present and severe congenital muscular dystrophy has been reported.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VIII <disease> An x-linked recessive hepatic glycogen storage disease resulting from lack of expression of phosphorylase-b-kinase activity. Symptoms are relatively mild; hepatomegaly, increased liver glycogen, and decreased leukocyte phosphorylase are present. Liver shrinkage occurs in response to glucagon.
Inheritance: X-linked recessive
(12 Dec 1998)
V-type ATPase <enzyme> From eukaryotic endomembrane systems, including vacuoles, lysosomes, golgi apparatus, chromaffin granules and coated vesicles. One of three major classes of ion transport ATPase, characterised by a multi subunit structure and a lack of a phosphorylated intermediate.
Found in archaebacteria but not eubacteria, in the intracellular acidic vacuoles and in some proton pumping epithelia (e.g. Intercalated cells of kidney). A complex enzyme encoded by several genes, involved in ion translocation but does not act via phosphorylated enzyme intermediate
See: P-type ATPase.
Registry number: EC 3.6.1.-
Synonym: atpase, v-type, atpase, vacuolar, vacuolar atpase, v-atpase, vacuolar h+-atpase, vacuolar membrane h(+)-atpase, vha55 gene product, vma16 gene product
(26 Jun 1999)
Gm type <immunology> Genetically determined allotypic antigens found on IgG of some individuals.
(18 Nov 1997)
Golgi type II neuron <physiology> Nerve cells with short axons which ramify in the gray matter.
(05 Mar 2000)
Golgi type I neuron <physiology> Nerve cells whose long axons leave the gray matter of which they form a part.
(05 Mar 2000)
membrane-type 3 matrix metalloproteinase <enzyme> Sm3 is a soluble form of mt3-mmp, probably an alternatively sliced variant.
Registry number: EC 3.4.24.-
Synonym: mt3-mmp, sm3-mmp
(26 Jun 1999)
membrane-type 4 matrix metalloproteinase <enzyme> Cloned from breast carcinoma.
Registry number: EC 3.4.24.-
Synonym: mt4-mmp, mmp-17 gene product, mmp-17
(26 Jun 1999)
membrane-type matrix metalloproteinase <enzyme> Activates gelatinase a; isolated from a human placenta cdna gene library; contains a transmembrane domain; do not use for any other numbered matrix metalloproteinases; genbank d26512
Registry number: EC 3.4.24.-
Synonym: mt-mmp, mmp-x1 protein, matrix metalloproteinase, membrane-type, mmp14 gene product, mmp-14 gene product, mt1-mmp, matrix metalloproteinase 14, mt2-mmp, mmp15 gene product, mmp16 gene product
(26 Jun 1999)
retroviruses type b, mammalian A genus of the family retroviridae consisting of a few exogenous, vertically transmitted and endogenous viruses of mice. It is associated with mammary carcinoma and T-cell lymphoma.
(12 Dec 1998)
retroviruses type c, avian A genus of the family retroviridae with type c morphology, that causes malignant and other diseases in wild birds and domestic fowl.
(12 Dec 1998)
retroviruses type c, mammalian A genus of retroviridae comprising endogenous sequences in mammals, related reticuloendotheliosis viruses of birds, and a reptilian species. Many species contain oncogenes and cause leukaemias and sarcomas.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • deoxyribonucleic acid
    µð¿Á½Ã¸®º¸ ÇÙ»ê
  • dichlorophenlxyacetic acid
    (È­)µðŬ·Î·ÎÆä³ì½Ã¾Æ¼¼Æ®»ê(±× ³ªÆ®·ý¿°Àº Á¦ÃÊÁ¦)
  • essential amino acid
    (È­)Çʼö ¾Æ¹Ì³ë»ê
  • ethacrynic acid
    (¾à)¿¡Å¸Å©¸°»ê
  • fatty acid
    Áö¹æ»ê
  • folic acid
    ¿±»ê(ºóÇ÷ÀÇ Æ¯È¿Á¦)
  • formic acid
    Æ÷¸§»ê
  • fulminic acid
    ³ú»ê
  • fumaric acid
    Ǫ¸¶¸£»ê
  • gallic acid
    °¥»ê
  • glacial acetic acid
    ºùÃÊ»ê
  • glutamic acid
    ±Û·çŸ¹Î»ê
  • hyaluronic acid
    È÷¾Ë·ç·Ð»ê (»ê¼º´ç·ù)
  • hydriodic acid
    ¿ÁÈ­ ¼ö¼Ò»ê
  • hydrochloric acid
    ¿°»ê
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á